Preview

PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology

Advanced search

PHARMACOECONOMICS. Modern Pharmacoeconomics and Pharmacoepidemiology

The journal is the first and most reputable in Russia and EurAsEC (Eurasian Economic Community) countries peer-reviewed periodical that publishes materials on new medical technologies, economic optimization of drug therapy, quality-of-life and healthcare problems. 

The journal was founded in 2008.

The impact factor of this journal, as shown in the Russian Science Citation Index (RSCI) is the highest among the periodicals in the areas of pharmacoeconomics, health technology assessment, and epidemiology. According to RSCI, the biennial impact factor (without self-citations) was 0.325 in 2013, 0.411 in 2014, and 0.722 in 2015.

The journal publishes various materials on pharmacoeconomics and pharmaco-epidemiology including the methodology, data analysis and results of studies on public health, medical technologies and economic aspects of drug therapies. The original articles and literature reviews cover Cost-of-Illness Analysis, Cost-Minimization Analysis, Cost-Effectiveness Analysis (CEA), Cost-Utility Analysis (CUA), Cost-Benefit Analysis (CBA), Quality of Life Assessment (QoL), Patients' Preferences & Patients’ Satisfaction indices and related topics. 

Our aims and priorities focus on scientific and information support to the decision-makers and experts in public drug supply, health providers, research and education professionals, as well as pharmaceutic and insurance companies. 

Languages: Russian, English 

Periodicity: 4 issues per year (quarterly). 

Copies of this journal are distributed under the Creative Commons Attribution 4.0 License: full-text materials are freely available to the public in an open access repository.

Distribution of the printed version: Russia, the EurAsian Economic Community countries (Belarus, Kazakhstan, Kyrgyzstan, Tajikistan, Uzbekistan, Armenia, Moldova) 

The editorial board of PHARMACOECONOMICS. Modern Pharmacoeconomics and Pharmacoepidemiology” includes leading experts in pharmaco-economics, clinical pharmacology, medical technology assessment, epidemiology, and public health from Russia, USA and Spain.

The editorial board maintains the policy of full compliance with all principles of publishing ethics. Our ethical standards and codes conform to those of top international science publishers. 

All submitted materials undergo a mandatory double-blind peer review

Media Certificate of Registration: ПИ №ФС77-32713 of August 01, 2008.
ISSN 2070-4909 (Print)
ISSN 2070-4933 (Online) 

By the decision of the Higher Attestation Commission (HAC) of Russia, PharmacoEconomics. Modern Pharmacoeconomics and Pharmacoepidemiology is included in the "List of top peer-reviewed scientific journals and publications" where scientists seeking academic degrees are required to publish their results. 

The journal appears in the Russian Universal Scientific Electronic Library (RUNEB) elibrary.ru and is also present in the database of the Russian Science Citation Index (RSCI). Concise versions of major articles from this journal are published by the All-Russian Institute for Scientific and Technical Information (VINITI). The journal is also indexed by "Ulrich's periodicals Directory" – a global information system of periodicals and continued publications.

 

Current issue

Vol 11, No 4 (2018)

Original Article

62-70 51
Abstract

Fabry disease (FD) is a severe lysosome storage disease caused by congenital deficiency of the enzyme α-galactosidase A and characterized by the risk of renal failure combined with cardiovascular and CNS complications. According to the currently available information, the early start of enzyme replacement therapy (ERT) leads to a significant improvement in patient’s condition.

The aim of the study is to assess whether the timely ERT prevents severe FD complications and to calculate the number of prevented cases as depending on the time of ERT start.

Materials and methods. The proposed model is based on the published results on patients with FD, receiving agalsidase alpha as ERT (no data for agalsidase beta was found). The expected number of cases with life-threatening complications was calculated for different starting timepoints and durations of the ERT.

Results. In patients with FD, continuous ERT during five years reduces the number of serious cardiovascular and renal complications by 25%. An early start of ERT makes it possible to additionally (as compared with a late start) prevent the complications in more than 20% of cases.

Conclusion. The early initiation of RPT in patients with FD can significantly reduce the occurrence of severe lifethreatening complications, increase the patients’ survival and improve their quality of life.